Compare Procter & Gamble Health with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs STRIDES PHARMA SCIENCE - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH STRIDES PHARMA SCIENCE PROCTER & GAMBLE HEALTH/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 18.3 44.7 40.9% View Chart
P/BV x 7.4 2.1 352.6% View Chart
Dividend Yield % 6.4 0.2 2,767.4%  

Financials

 PROCTER & GAMBLE HEALTH   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
STRIDES PHARMA SCIENCE
Mar-18
PROCTER & GAMBLE HEALTH/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs3,5491,147 309.4%   
Low Rs1,301642 202.7%   
Sales per share (Unadj.) Rs511.4317.2 161.2%  
Earnings per share (Unadj.) Rs61.37.8 781.3%  
Cash flow per share (Unadj.) Rs74.025.1 295.4%  
Dividends per share (Unadj.) Rs440.002.00 22,000.0%  
Dividend yield (eoy) %18.10.2 8,114.5%  
Book value per share (Unadj.) Rs927.8274.3 338.3%  
Shares outstanding (eoy) m16.6089.50 18.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.72.8 168.2%   
Avg P/E ratio x39.6114.0 34.7%  
P/CF ratio (eoy) x32.835.7 91.8%  
Price / Book Value ratio x2.63.3 80.1%  
Dividend payout %717.925.5 2,815.9%   
Avg Mkt Cap Rs m40,25780,058 50.3%   
No. of employees `0001.12.5 45.2%   
Total wages/salary Rs m1,3134,341 30.2%   
Avg. sales/employee Rs Th7,486.711,325.8 66.1%   
Avg. wages/employee Rs Th1,157.61,731.4 66.9%   
Avg. net profit/employee Rs Th897.2280.1 320.4%   
INCOME DATA
Net Sales Rs m8,49028,394 29.9%  
Other income Rs m244941 25.9%   
Total revenues Rs m8,73429,334 29.8%   
Gross profit Rs m1,4823,965 37.4%  
Depreciation Rs m2111,540 13.7%   
Interest Rs m01,962 0.0%   
Profit before tax Rs m1,5141,403 107.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m66-436 -15.1%   
Tax Rs m56397 578.1%   
Profit after tax Rs m1,017702 144.9%  
Gross profit margin %17.514.0 125.0%  
Effective tax rate %37.16.9 535.7%   
Net profit margin %12.02.5 484.6%  
BALANCE SHEET DATA
Current assets Rs m15,34324,836 61.8%   
Current liabilities Rs m1,96018,993 10.3%   
Net working cap to sales %157.620.6 766.0%  
Current ratio x7.81.3 598.6%  
Inventory Days Days4971 68.7%  
Debtors Days Days28113 25.1%  
Net fixed assets Rs m1,20934,289 3.5%   
Share capital Rs m166895 18.5%   
"Free" reserves Rs m15,23523,651 64.4%   
Net worth Rs m15,40124,546 62.7%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m17,59565,437 26.9%  
Interest coverage xNM1.7-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.50.4 111.2%   
Return on assets %5.84.1 142.0%  
Return on equity %6.62.9 230.9%  
Return on capital %10.36.9 148.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63615,697 10.4%   
Fx outflow Rs m4,368735 594.0%   
Net fx Rs m-2,73214,962 -18.3%   
CASH FLOW
From Operations Rs m-1,3041,871 -69.7%  
From Investments Rs m12,6975,826 217.9%  
From Financial Activity Rs m-301-10,157 3.0%  
Net Cashflow Rs m11,093-2,615 -424.2%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 37.8 48.1%  
FIIs % 1.0 8.6 11.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 25.9 112.4%  
Shareholders   28,591 56,241 50.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   SANOFI INDIA  TORRENT PHARMA  DISHMAN PHARMA  CIPLA  ABBOTT INDIA  

Compare PROCTER & GAMBLE HEALTH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 200 Points Higher; Dow Futures Up by 103 Points(12:30 pm)

Share markets in India are presently trading on a strong note. The BSE Sensex is trading up by 246 points, up 0.5% at 51,027 levels.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Penny Stock Master Series: The Quest for 10X Profits in 10 Years(Profit Hunter)

Feb 12, 2021

This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Feb 25, 2021 01:40 PM

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH - NATCO PHARMA COMPARISON

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS